Archive for the ‘Gene Therapy Research’ Category

Life and Learning Systems (4) - Co-evolution of Language and Brain_short.avi
This is the shortened version of the 4th video in the Life and Learning Systems series. In this video I introduce Terrence Deacon #39;s idea of how relaxed selection could have played a role in weakening the constraints of genetics and accelerated the brain #39;s evolution, in particular as it relates to the brain #39;s symbolic capacity. This is the first video in this series to begin examining symbolic capacity, and as an extension linguistic capacity, and how this capacity is dependent upon elements external, yet connected, to the body. Notes: docs.google.com Presentation: docs.google.comFrom:morellidjejuViews:1 0ratingsTime:16:39More inEducation

Excerpt from:
Life and Learning Systems (4) - Co-evolution of Language and Brain_short.avi - Video

High-throughput phenotyping at The Plant Accelerator®
The Plant Accelerator, headquarters of the Australian Plant Phenomics Facility, was built to help alleviate the phenotyping bottleneck and accelerate advances in crop physiology and genetics. It houses fully automated imaging and watering systems, allowing large scale phenotypic screens under various stress conditions, such as salinity or water stress. Important traits, such as relative growth rate or water use efficiency can be measured non-destructively over time in a throughput that allows genetic screenings.From:LemnaTec2008Views:0 0ratingsTime:20:01More inScience Technology

View post:
High-throughput phenotyping at The Plant Accelerator® - Video

Genetics-Iran-11-04-2012
Iranian scientists have been working in the field of genetics for half of a century. Today the institute of genetic engineering and biotechnology is one of the leading research centers in the region. Its activities are aimed at enhancing the quality of life by better food medicine and environment. Amir Mehdi Kazemi reports on genetic engineering and biotechnology in Iran. Follow our Facebook on: http://www.facebook.com Follow our Twitter on: twitter.comFrom:FullWorldNewsViews:0 0ratingsTime:06:41More inNews Politics

See the article here:
Genetics-Iran-11-04-2012 - Video

Evolution - Occam #39;s razor
"Rejecting evolution expresses more than an inability to think critically; it relies on a fundamentally paranoid worldview. Think what the world would have to be like for evolution to be false. Almost every scientist on earth would have to be engaged in a fraud so complex and extensive it involved every field from archaeology, paleontology, geology and genetics to biology, chemistry and physics. And yet this massive concatenation of lies and delusion is so full of obvious holes that a pastor with a Bible-college degree or a homeschooling parent with no degree at all can see right through it." Source: http://www.patheos.com Music is Mozart #39;s Eine Kleine Nachtmusik, Second MovementFrom:TryzonUncutViews:0 0ratingsTime:00:33More inEducation

Follow this link:
Evolution - Occam's razor - Video

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced that its collaborator, Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, announced that the European Commission has granted conditional marketing authorization for ADCETRIS (brentuximab vedotin). ADCETRIS was approved for two indications: (1) the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). As a result, under the collaboration Seattle Genetics will receive two milestone payments from Millennium, one for each indication, totaling $25 million. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.

The approval of ADCETRIS by the European Commission marks a significant milestone for the product and for the many relapsed or refractory HL and systemic ALCL patients in need of effective new treatment options in Europe, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. In addition to the U.S. and EU approvals of ADCETRIS, we are making regulatory progress for approval in Canada while Millennium and Takeda are pursuing regulatory approvals in other countries. Complementing these regulatory activities is a robust ADCETRIS clinical development program to support our goal of establishing it as the foundation of therapy for CD30-positive malignancies.

The conditional marketing authorization for ADCETRIS is valid in the 27 member states of the European Union (EU) as well as Norway, Liechtenstein and Iceland. Similar to accelerated approval regulations inthe United States, conditional marketing authorizations are granted in the EU to medicinal products that fulfill an unmet medical need with a positive benefit/risk assessmentand whose immediate availability would result in a significant public health benefit. Conditional marketing authorization by the European Commission includes obligations to provide additional clinical data at a later stage to confirm the positive benefit-risk assessment. The ADCETRIS Marketing Authorization Application was filed by Takeda Global Research & Development Centre (Europe) to the European Medicines Agency.

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

ADCETRIS received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2011 for relapsed HL and sALCL.

Seattle Genetics and Millennium are jointly developing ADCETRIS. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and the Takeda Group has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and the Takeda Group are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where the Takeda Group will be solely responsible for development costs. Seattle Genetics is entitled to royalties based on a percentage of Millennium's net sales in its territory at rates that range from the mid-teens to the mid-twenties based on sales volume, subject to offsets for royalties paid by Millennium to third parties.

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The FDA granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at http://www.seattlegenetics.com.

Read more:
Seattle Genetics Announces ADCETRIS® Receives European Commission Conditional Marketing Authorization

Public release date: 5-Nov-2012 [ | E-mail | Share ]

Contact: Ben Norman Sciencenewsroom@wiley.com 44-124-377-0375 Wiley

John Wiley & Sons, Inc., today announced the launch of Molecular Genetics & Genomic Medicine (MGGM), a new Wiley Open Access journal. Under the leadership of Editor-in-Chief Dr. Maximilian Muenke, the journal will provide rapid dissemination of high-quality research in all areas of human, medical and molecular genetics.

Dr. Muenke, a renowned medical geneticist, trained in pediatrics in his native Germany and then pursued postdoctoral fellowship training in human and clinical genetics at Yale and the University of Pennsylvania. He is now based at a leading research organization in Bethesda, USA.

Dr. Muenke's group identified several genes important in craniofacial disorders including one of the most common, now termed Muenke syndrome. More recently, his lab has identified susceptibility genes for the most common childhood behavioral disorder, Attention-Deficit/Hyperactivity Disorder (ADHD), with further research focused on predicting severity, treatment, and long-term outcome.

Working alongside an international editorial board of experts in diverse areas of human and medical genetics and genomics, Dr. Muenke will oversee the rigorous peer-review and evaluation of articles submitted for publication in MGGM.

"I am extremely excited about being the founding editor of this new journal," says Dr. Muenke. "Since there is not a single disorder that does not have a genetic origin, I believe that the fields of molecular genetics and genomic medicine will be expanding into virtually all medical specialties. MGGM will grow as well, with articles on diseases from diagnosis to treatment, as a step toward personalized medicine. "

Molecular Genetics & Genomic Medicine is the latest addition to Wiley's portfolio of genetics journals and will benefit from relationships with widely respected titles including the American Journal of Medical Genetics and Human Mutation.

"We're delighted to expand our open access portfolio with the addition of this important new journal," said Rachel Burley, Vice President and Director, Open Access, Wiley. "Under the expert editorial leadership of Dr. Muenke, Molecular Genetics & Genomic Medicine will make a valuable contribution to the literature."

###

Continue reading here:
Molecular Genetics & Genomic Medicine: New open access journal launched by Wiley

LOS ANGELES, Nov. 5, 2012 /PRNewswire/ --Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the launch of testing for ROS1 gene rearrangements. Recently, the Massachusetts General Hospital Cancer Center ("MGH") published studies showing that ROS1 driven tumors are sensitive to the FDA approved drug XALKORI1 (crizotinib)2 to treat non-small-cell lung cancer ("NSCLC") patients with ALK gene rearrangements. Tumors driven by rearrangements in the ROS1 gene represent an additional 1 to 2 percent of patients who may be candidates for crizotinib therapy.3 The company will offer both fluorescence in situ hybridization ("FISH") and polymerase chain reaction ("PCR") based ROS1 translocation testing.

"We are pleased to add ROS1 to our growing test menu," said Thomas Bologna, chairman and CEO of Response Genetics. "We believe the dual option of FISH and PCR represent a unique offering and is consistent with our Leave No Stone Unturned program whereby we go to great lengths to help patients receive optimal therapy. While FISH is the technology that has been used for ROS1 to date, PCR has the advantage of providing additional information about the variant found, information that may be useful for evaluating response and resistance mechanisms.This promising new marker is now readily available to pathologists and oncologists seeking fast turnaround time and utilizes the company's proprietary methods that enable results on very small biopsies including fine needle aspirates."

ROS1 supplements the company's recently introduced Leave No Stone Unturned program, in which patients whose tumors test negative for the ALK Break Apart FISH assay receive follow-up ALK testing using the company's proprietary EML4-ALK RT-PCR-based assay at minimal additional cost. With the addition of ROS1, ordering clinicians can now make a more complete evaluation of each of their NSCLC patients as candidates for crizotinib therapy.

1 XALKORI is a registered trademark of Pfizer, Inc. 2 Bergethon et. al. "ROS1 rearrangements define a unique molecular class of lung cancers." Journal of Clinical Oncology 2012 Mar 10;30(8):863-70. Epub 2012 Jan 3. 3 Ibid

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic tests for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomics testing services of clinical-trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to continue to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to strengthen marketing capabilities, to expand the suite of ResponseDX products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, and to continue to execute on its business strategy and operations, to continue to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Originally posted here:
Response Genetics, Inc. to Offer ROS1 Testing for Lung Cancer

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced that more than a dozen abstracts, in addition to several collaborator abstracts, for both ADCETRIS (brentuximab vedotin) and investigational antibody-drug conjugates (ADCs) will be presented at the American Society of Hematology (ASH) Annual Meeting taking place in Atlanta, Georgia, December 8 11, 2012. ADCETRIS is an ADC directed to CD30, which is known to be expressed in Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL), as well as in some types of cutaneous T-cell lymphoma (CTCL), B-cell lymphomas and mature T-cell lymphomas (MTCL). Seattle Genetics is broadly evaluating CD30 expression in many other cancer types. ADCETRIS is currently not approved for use in CTCL, B-cell lymphomas, and front-line treatment of HL or MTCL.

"The comprehensive data presented at ASH 2012 support our goal to establish ADCETRIS as the foundation of therapy for a broad array of CD30-positive malignancies and redefine therapy in the front-line setting of HL and MTCL, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "As a pioneer in developing ADC therapies, we continue to innovate by expanding the ADCETRIS program into CD30-positive malignancies, advancing additional ADC pipeline candidates, and supporting the progress of our collaborator ADC programs. These important advances represent our continued innovation and ADC leadership position."

Seattle Genetics is the leader in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Of the approximately 30 ADC candidates currently in development, more than half utilize Seattle Genetics proprietary ADC technology. Multiple company, investigator and collaborator presentations will be presented at ASH, including data on ADCETRIS in many types of CD30-positive malignancies and preclinical data from a new ADC product candidate called SGN-CD33A. Abstract presentations planned at ASH can be found at http://www.hematology.org and include the following:

ADCETRIS Data in the Front-line Setting

ADCETRIS Data in CTCL

ADCETRIS Data in Hodgkin and Non-Hodgkin Lymphomas

Data on Other ADC Candidates and Collaborator Programs

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Read more from the original source:
Seattle Genetics’ ASH 2012 Presentations Highlight ADCETRIS® and Demonstrate Leadership in the Development of Antibody ...

LOS ANGELES, Nov. 6, 2012 /PRNewswire/ --Response Genetics, Inc. (RGDX),a company focused on the development and commercialization of molecular diagnostic tests for cancer, will announce its third quarter financial results and give an operational update in a press release to be issued before the market opens on Tuesday, November 13, 2012. The company will host a conference call that same day at 10:00 a.m. EST to discuss its financial results.

Conference Call Details

To access the conference call by phone on November 13 at 10:00 a.m. EST, dial (800) 537-0745 or (253) 237-1142 for international participants. A telephone replay will be available beginning approximately two hours after the call through November 20, and may be accessed by dialing (855) 859-2056 or (404) 537-3406. The conference passcode for both the live call and replay is 57580014.

To access the live and archived webcast of the conference call, go to the Investor Relations section of the Company's website at http://investor.responsegenetics.com. It is advised that participants connect at least 15 minutes prior to the call to allow for any software downloads that might be necessary.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Read this article:
Response Genetics, Inc. to Release Third Quarter Financial Results and Host Conference Call on November 13, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Metamark Genetics, Inc., a privately held, oncology-focused molecular diagnostics company, announced today that it has closed a $13 million series B financing led by current and new private investors. The proceeds from this round will enable the company to further refine its novel, protein-based prostate cancer prognostic tests and complete final clinical validation work. The company is developing two separate prognostic tests. The first is designed to use prostate cancer biopsy tissue to help physicians more accurately determine if patients have a slow-growing or aggressive form of prostate cancer, thereby improving treatment decisions. The second is designed to predict the longer-term course of disease.

This new funding comes on the heels of Metamark successfully completing important proof-of-concept work last spring, said Kenneth Weg, Metamark co-founder and founding chairman of the board of directors. This enables us to proceed with diagnostic and drug target research at an accelerated rate and moves us closer to our goal of achieving commercialization of the Metamark prostate cancer test.

Leadership and board appointments

In conjunction with closing the financing, the company announced changes to the board of directors and the resignation of Mark Straley as president and CEO. Straley resigned to pursue other opportunities and Metamark is conducting a search for a new CEO to lead the company into commercialization and further development.

Michael Kauffman, M.D., Ph.D., joined the Metamark Genetics board of directors and will serve as interim executive director until a new company president and CEO is appointed. Kauffman was vice president of medicine and an early employee at Millennium Predictive Medicine, the diagnostics and pharmacogenomics arm of Millennium Pharmaceuticals Inc. where he co-led collaborations with Becton Dickinson and Bristol-Myers Squibb. More recently, Dr. Kauffman co-founded Karyopharm Therapeutics, a pharmaceutical company developing novel oncology drugs. He was previously chief medical officer of Proteolix Pharmaceuticals and Onyx Pharmaceuticals Inc., where he oversaw the clinical development of carfilzomib. He received his M.D. and Ph.D. from Johns Hopkins Medical School and is board certified in internal medicine.

Greg Critchfield, M.D., M.S., was appointed as lead director of the board. Dr. Critchfield has served on the Metamark board since September 2010. Previously he served as president and board member of Myriad Genetic Laboratories, Inc., the diagnostic subsidiary of Myriad Genetics, Inc., where he was responsible for building scientific, medical, and commercial capabilities and launching seven novel molecular diagnostic products across a variety of technology platforms. Prior to Myriad, he served as chief medical and science officer with responsibility for science, medicine, and innovation at Corning Clinical Laboratories, which later became Quest Diagnostics, Inc. Dr. Critchfield received a bachelor's degree in Microbiology with a minor in Chemistry from Brigham Young University, a M.D. degree from the University of Utah, and a master's degree in Biophysical Sciences at the University of Minnesota. He currently serves as CEO of Sera Prognostics, Inc., and is an independent director of a number of innovative life sciences companies.

Commenting on the leadership changes, Dr. Critchfield stated, Mark has led the company to achieve critical clinical and commercial milestones and we thank him for his contributions and wish him the very best with his future endeavors. He continued, During this time of transition, we are pleased to have Kens continued leadership on our board. He has served as board chairman since the company was formed and has been a rallying foundation for the company. We also feel fortunate to have an individual of Michaels talents and accomplishments serve in this interim leadership capacity as we complete validation of the strong clinical diagnostics foundation built by the Metamark Founders and employees.

About Metamark Genetics, Inc.

Metamark is a privately held oncology company focused on the development of molecular function-based prognostic assays for early staged cancers. The MetamarkDx Prognostic Assays under development are based on Metamarks proprietary Prognosis Determinants, genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread. For further information, please visit the companys website at http://www.metamarkgenetics.com.

Continued here:
Metamark Genetics Completes $13 Million Series B Financing; Announces Leadership Changes

SALT LAKE CITY, Nov. 5, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) today announced results for its first fiscal quarter ended September 30, 2012. Revenue for the first fiscal quarter increased 21 percent over the same period in the prior year to $133.4 million. First fiscal quarter earnings per diluted share were $0.36, an increase of 24 percent over the same period of the prior year.

"In what has historically been a challenging summer quarter, Myriad achieved record revenue and higher operating profits," said Peter D. Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "We believe that our initiatives of growing existing tests and markets have fueled these strong financial results and we continue to be excited about the future potential contributions from our strategic directives of expanding internationally and launching new tests across a diverse set of major disease indications."

First Fiscal Quarter 2013 Results

Business Highlights during the First Quarter of Fiscal 2013

Fiscal Year 2013 Outlook

The Company has increased its expectations for fiscal year 2013 financial performance. Total revenue is now expected to be in a range of $570 million to $585 million, an increase from the original fiscal 2013 guidance of $550 million to $565 million. This level of revenue is expected to result in diluted earnings per share of $1.50 to $1.55, up from the original guidance of $1.44 to $1.48 per share. An important part of the Company's customer base in the Eastern United States has been affected by the recent severe storm. Although the impact of this event on the Company's future revenues is not yet determinable, it believes that the effect will be short-term in nature and the potential impact was considered in the revised fiscal year 2013 outlook. These projections are forward looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release. The Company will provide further detail on its business outlook during the conference call it is holding today to discuss its fiscal 2013 first quarter financial results.

Conference Call and Webcast

A conference call will be held on Monday, November 5, 2012, at 4:30 p.m. Eastern Time to discuss Myriad's financial results for the first fiscal quarter of 2013. The dial-in number for domestic callers is (800) 354-6885. International callers may dial (303) 223-2680. All callers will be asked to reference reservation number 21607424. An archived replay of the call will be available for seven days by dialing (800) 633-8284 and entering the reservation number above. The conference call will also be available through a live Webcast at http://www.myriad.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Excerpt from:
Myriad Genetics Reports First Quarter Fiscal Year 2013 Results

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics, Inc. (ILIU) announced today that it will host a conference call and Webcast on Wednesday, November 14, 2012 at 4:30 p.m. ET to discuss the Companys third quarter results.

To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of Interleukin Genetics, Inc.s Website at http://www.ilgenetics.com.

About Interleukin Genetics Interleukin Genetics, Inc. (ILIU) develops and markets a line of genetic tests under the Inherent Health and PST brands.The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.

Originally posted here:
Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2012 Results

Lysosomal Storage Disorders
ll4.me Lysosomal Storage Disorders From Lysosomes to Storage Diseases and Back: A Personal Reminiscence.- Lysosomal Biogenesis and Disease.- The Concept of Treatment in Lysosomal Storage Diseases.- Complex Lipid Catabolism.- Retroviral Vectors for Gene Therapy.- Adenovirus in Gene Therapy.- Setting Back the Clock: Adenoviral-Mediated Gene Therapy for Lysosomal Storage Disorders.- Adeno-Associated Viral-Mediated Gene Therapy of Lysosomal Storage Disorders.- Herpes Simplex Virus Vectors for Gene Therapy of Lysomal Storage Disorders.- Gene Therapy of Lysosomal Storage Disorders by Lentiviral Vectors.- Substrate Reduction Therapy.- Newborn Screening for Lysosomal Storage Disorders.- Genetic Counseling for Lysosomal Storage Diseases.- Neural Stem Cell Therapy in Lysosomal Storage Disorders.- The GM1 Gangliosidoses.- The GM2 Gangliosidoses.- Acid Sphingomyelinase-Deficient Niemann-Pick Disease.- Krabbe Disease (Globoid Cell Leukodystrophy).- Metachromatic Leukodystrophy.- Fabry Disease.- Gaucher Disease: Review and Perspectives on Treatment.- Therapeutic Goals in the Treatment of Gaucher Disease.- The Neuronal Ceroid Lipofuscinoses: Clinical Features and Molecular Basis of Disease.- Mucopolysaccharidosis I.- Mucopolysaccharidosis II.- Sanfilippo Syndrome: Clinical Genetic Diagnosis and Therapies.- Mucopolysaccharidosis IV (Morquio Syndrome; MPS IV).- Mucopolysaccharidosis Type VI (MPS VI, Maroteaux-Lamy Syndrome).- Mucopolysaccharidosis Type VII (Sly Disease): Clinical, Genetic ...From:davidbrown9865Views:0 0ratingsTime:00:13More inPeople Blogs

View original post here:
Lysosomal Storage Disorders - Video

James Bond - Die Another Day Watch Online Free, part 1 of 7, full lenght movie
James Bond - Die Another Day In the pre-title sequence, James Bond and his two South Korean allies infiltrate a North Korean military base belonging to Colonel Tan-Sun Moon, an army officer who is illegally selling weaponry in exchange for African conflict diamonds. Bond poses as a weapons dealer, rigging his briefcase of diamonds with C4. He meets Moon and his assistant, Zao. After the diamonds are handed over, Zao discovers Bond #39;s true identity and informs Moon. Fearing retribution from his father, General Moon, the Colonel then flees in a large hovercraft. Bond detonates the C4, embedding several diamonds in Zao #39;s face. He then steals another hovercraft and chases Moon, who tumbles into a waterfall. Soon after, North Korean troops capture Bond under General Moon #39;s orders and he is imprisoned and tortured. Fourteen months later, Bond is released in exchange for Zao, who was captured during that time. He is sedated and taken to meet M, who informs him that his status as a 00 Agent is suspended due to her belief that he may have leaked information under duress. Still bitter over Zao #39;s release, Bond decides to complete his mission by evading MI6 #39;s security and travels to Cuba. He traces Zao to an island called Isla Los Organos, known for its gene therapy "Clinic" which allows patients to have their appearances changed. On the coast, he meets a NSA agent Giacinta #39;Jinx #39; Johnson. With her help, Bond locates Zao #39;s room inside the clinic and briefly tortures him. Zao flees in aFrom:glasefclerko1986Views:0 0ratingsTime:04:06More inEntertainment

Follow this link:
James Bond - Die Another Day Watch Online Free, part 1 of 7, full lenght movie - Video

CF Gene Therapy
News clip on new gene therapy shot coming next year to treat CF possibly...From:AH FrenchViews:0 0ratingsTime:02:25More inEducation

View original post here:
CF Gene Therapy - Video

The world's first mass-market gene therapy has been legalized in Europe. Glybera, which treats a painful disorder that leads to pancreatitis, will be available in hospitals beginning next year.

Chances are you haven't heard much about lipoprotein lipase deficiency (LPLD), a disease that leads to pancreatitis. This rare disease, however, is at the center of world-changing medical advances.

Last week the European Union approved a gene therapy treatment for LPLD--and this marks the first time any medical treatment that rewrites a patients' DNA has been approved for commercial use.

The treatment, called Glybera, will be released by Dutch firm uniQure in the second half of 2013. Glybera will be administered to patients by specially trained doctors at a limited number of European hospitals. Patients receiving treatment have their DNA altered by a series of injections into their leg muscles, which helps normalize the metabolism of fat particles carried in the blood. LPLD prevents sufferers from properly metabolizing these particles, leading to a host of side effects including pancreatitis.

Gene therapy is an emerging form of medicine, focusing on the use of DNA to rewrite or supplement existing genes. This experimental practice is expected to lead to a series of breakthroughs over the next 50 or so years for various types of cancers, Parkinson's disease, sickle cell anemia, and a host of inherited conditions. Studies involving different forms of gene therapy are currently under way in Europe and the United States--one famous case in 2007 involved a man who was cured of HIV through stem cell transplantation. Stem cell transplants are one type of gene therapy used to give patients therapeutic DNA; other methods use different sources.

LPLD affects approximately one in 1,000,000 people worldwide. Apart from (frequently fatal) acute pancreatitis, patients regularly suffer from yellow spots on their skin, swollen abdomens, enlarged livers, severe abdominal pain, and diarrhea. The condition is currently treated through diet--patients are encouraged to go on a strict low-fat, alcohol-and-red-meat-free diet to mitigate symptoms.

By helping to normalize the metabolism of fat, Glybera prevents inflammation of the pancreas thereby averting the associated pain and suffering and, if administered early enough, the associated co-morbidities, said Professor John Kastelein of the University of Amsterdam in a statement.

Gene therapy treatments in the United States are primarily focused on cancer, including leukemia. No other gene therapy products are expected to be approved by major medical regulator agencies in 2012. The European Commission, which handles medical approvals for Europe, is widely considered to have a bureaucratic pipeline that is far more open to gene therapy than the United States.

[Image: DNA damage via Tom Ellenberger/Washington University School of Medicine]

For more stories like this, follow @fastcompany on Twitter. Find Neal Ungerleider, the author of this article, on Twitter.

Go here to see the original:
DNA Hacking Is Now Street Legal

A gene-therapy medicine has been given commercial approval in Europe for the first time.

The treatment, Glybera, is designed to help those suffering from lipoprotein lipase deficiency -- an inherited disorder which sees patients unable to break down fats and can lead to life-threatening pancreatitis attacks.

Glybera -- the brand name for alipogene tiparvovec -- works on the genetic level by using a virus to implant working copies of the lipoprotein lipase gene into muscle cells, thus enabling production of the enzyme in those cells.

The first country to approve a gene therapy for commercial use was China in 2003 but gene therapy in Europe has, until now, been restricted to research laboratories.

Jorn Aldag, CEO of Glybera creators UniQure, said: "The final approval of Glybera from the European Commission marks a major step forward in making gene therapies available not only for lipoprotein lipase deficiency, but also for a large number of rare diseases with a very high unmet medical need."

The treatment is expected to come to market in 2013.

Image: Shutterstock

Here is the original post:
First commercial gene therapy approved for Europe

Dutch biotech company uniQure said Monday it would start selling the first human gene therapy to be approved in the West by mid-2013 and predicted an explosion of similar therapies to come.

The European Commission approved Glybera on October 25, making the drug for treating the extremely rare disorder lipoprotein lipase deficiency (LPLD) the first to be approved for sale in Europe or North America.

"We believe that after Glybera's approval gene therapy is at the beginning of a period of rapid growth similar to the development of the antibody business in the last decade," uniQure chief executive Joern Aldag said in a statement.

Gene therapy works by modifying a patient's DNA to combat a specific disease, and has been experimented with to treat everything from blindness to depression and brain wasting diseases.

But the relatively unknown treatments have struggled to obtain regulatory approval in the West, although authorities in China approved a gene therapy for treating head and neck cancer as long ago as 2003.

Gene medicine burst on the medical scene in the late 1990s and is one of the most alluring areas of biotechnology, offering the theoretical promise of blocking or reversing inherited disease.

But this new frontier has also been hit by occasional setbacks, notably an unexpected or uncontrollable response from the immune system.

So far, successes have been few, limited to single-gene disorders -- as opposed to complex multi-gene disorders that account for the commonest diseases.

Setbacks included the tragic death of an 18-year-old US volunteer, Jesse Gelsinger, in 1999, and the development of cancer among two French children treated for "bubble baby" syndrome, a chronic lack of immune defences.

Glybera treats LPLD, an inherited disease that affects around one or two people in a million, by preventing them from metabolising certain fat particles in the blood.

More:
First gene therapy to go on sale in Europe in 2013: company

ScienceDaily (Nov. 5, 2012) Gene therapy can be performed safely in the human salivary gland, according to scientists at the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health.

This finding comes from the first-ever safety, or Phase I, clinical study of gene therapy in a human salivary gland. Its results, published this week in the Proceedings of the National Academy of Sciences, also show that the transferred gene, Aquaporin-1, has great potential to help head and neck cancer survivors who battle with chronic dry mouth. Aquaporin-1 encodes a protein that naturally forms pore-like water channels in the membranes of cells to help move fluid, such as occurs when salivary gland cells secrete saliva into the mouth.

These initial results clear the way for additional gene therapy studies in the salivary glands. Although sometimes overlooked, salivary glands present an ideal target for gene therapy. They are easily accessible and, once a gene is introduced, it has no obvious escape route into the bloodstream, where it can have unintended consequences.

"You cannot imagine how fulfilling it is to jot down an idea on a napkin in 1991 and then see it enter a clinical trial and help people.," said Bruce Baum, D.M.D., Ph.D., lead author on the study and recently retired NIDCR scientist who spent the last 21 years moving gene therapy in the salivary glands from the research bench to the clinic. "Can a scientist ask for anything better?"

Baum's interest in helping head and neck cancer survivors dates to the early 1980s. While attending to patients in the NIDCR's Dry Mouth Clinic, Baum encountered numerous people with head and neck cancer who had received radiation therapy to shrink their tumors. The radiation, while effective in treating cancer, had inadvertently damaged nearby salivary glands, compromising their ability to secrete saliva into the mouth.

Baum said he was thoroughly frustrated at the time because he had no effective moisture-restoring treatments to offer most patients. They had beaten cancer, but the radiation had left them with a permanent parched sensation in their mouths that diminished their quality of life and often led to chronic oral problems, such as difficulty swallowing, inflammation, infection, bad breath, and pain.

In the early 1990s, as the first gene-therapy studies entered research clinics, Baum saw an opportunity to make a difference. An initial napkin sketch of the procedure and 15 years of research later, Baum and his colleagues had assembled a compelling scientific case in animal studies that the transferred Aquaporin-1 gene, once expressed, will create new water channels in the impermeable salivary gland cells and allow water to flow through them. After rigorous reviews by NIH and the U.S. Food and Drug Administration, the Phase I protocol was launched and the first patients treated in 2008.

The scientists gave 11 head and neck cancer survivors a single-dose injection of the Aquaporin-1 gene directly into one of their two parotid salivary glands, the largest of the major salivary glands. The gene was packaged in a disabled, non-replicating adenovirus, the cause of the common cold when intact but incapable of causing a cold in this case. As is standard in gene therapy studies, the virus served as the vector, or Trojan horse, to deliver the gene into the cells lining the salivary gland.

The scientists found that five participants had increased levels of saliva secretion, as well as a renewed sense of moisture and lubrication in their mouths, within the study's first 42 days, the period covered in this report. Of the six who didn't benefit from gene therapy, none had serious side effects. The most common side effect was a transient and relatively minor immune response against the disabled adenovirus.

"It is time to evaluate a different vector to deliver the Aquaporin-1 gene, one that will cause only a minimal immune response," said Baum. "But these data will serve as stepping stones for other scientists to improve on this first attempt in the years ahead. The future for applications of gene therapy in the salivary gland is bright. "

Original post:
First gene therapy study in human salivary gland shows promise

FAQ-10 of 19: Do Stem Cells Cause Cancer In Stem Cell Therapy?
youtu.be People ask us if stem cell therapy can CAUSE cancer, and they are wise to be wary, but stem cell therapy has been proving effective AGAINST cancer, and has not cause any known cases of cancer to-date. For more personalized information, visit StemCell-Asia.info now.From:Harvey WallbangerViews:0 0ratingsTime:01:06More inScience Technology

The rest is here:
FAQ-10 of 19: Do Stem Cells Cause Cancer In Stem Cell Therapy? - Video

FAQ-12 of 19: Are Our Stem Cell Doctors Qualified for Stem Cell Therapy?
youtu.be The straight answer to this question might surprise you, but only if you think stem cell therapy is something that was approved for certain patients THIS year. And for more surprising, encouraging details on stem cell therapies and your particular case, visit bit.ly today.From:Harvey WallbangerViews:0 0ratingsTime:00:55More inPeople Blogs

Read more from the original source:
FAQ-12 of 19: Are Our Stem Cell Doctors Qualified for Stem Cell Therapy? - Video

FAQ-11 of 19: Why Have Stem Cell Therapy in Thailand #39;s Stem Cell Clinic?
youtu.be A few gentle suggestions on why visiting the only European-licensed stem cell clinic in Thailand is a better choice for time, optimum results and budget. For more detailed answers about Thailand #39;s one licensed stem cell clinic, visit bit.lyFrom:Harvey WallbangerViews:0 0ratingsTime:01:16More inNonprofits Activism

See the original post here:
FAQ-11 of 19: Why Have Stem Cell Therapy in Thailand's Stem Cell Clinic? - Video

FAQ-13 of 19: What Stem Cell Therapy Will Be MY Stem Cell Treatment?
youtu.be This seeks to answer the #39;what do I need for ME? #39; question, although it is a personal question not readily answerable online, so for your questions, go to bit.lyFrom:Harvey WallbangerViews:0 0ratingsTime:01:28More inEducation

Here is the original post:
FAQ-13 of 19: What Stem Cell Therapy Will Be MY Stem Cell Treatment? - Video

FAQ-14 of 19: Do We Offer a Guarantee for Our Stem Cell Therapy?
youtu.be Yes, a reasonable guarantee is provided, and you can learn more of it in this video. When you want more than this, visit bit.ly for personalized details of how stem cell therapy can benefit you.From:Harvey WallbangerViews:0 0ratingsTime:01:15More inPeople Blogs

See the article here:
FAQ-14 of 19: Do We Offer a Guarantee for Our Stem Cell Therapy? - Video

FAQ-11 of 19: Why Is Thailand My Better Stem Cell Choice for Stem Cell Therapy?
youtu.be Why is Thailand a better choice for stem cell therapy, instead of Europe? A few gentle suggestions on why visiting the only European-licensed stem cell clinic in Thailand is a better choice for time, optimum results and budget. For more detailed answers about Thailand #39;s one licensed stem cell clinic, visit bit.lyFrom:John PepperViews:0 0ratingsTime:01:16More inPeople Blogs

See the article here:
FAQ-11 of 19: Why Is Thailand My Better Stem Cell Choice for Stem Cell Therapy? - Video